La acromatopsia es una enfermedad retiniana hereditaria que causa la pérdida de la agudeza visual, así como también de la visión central y de colores, y de la visión en buenas condiciones de iluminación.
Latest News
-
Summary of the 11th Annual Retinal Therapeutics Innovation Summit
Research NewsThe 11th annual Retinal Therapeutics Innovation Summit featured 25 presentations from industry professionals worldwide and more than 400 attendees.
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
Research NewsThe Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Research NewsInterim results for pediatric patients with CNGB3 mutations were encouraging
-
Pediatric Ophthalmologists Target Inherited Retinal Diseases
In the PressNew opportunities continue to develop in an evolving landscape.
-
AGTC Reports Encouraging Results from Phase 1/2 Gene Therapy Clinical Trial for Achromatopsia (CNGB3 Mutations)
Research NewsThe company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Improvements in Visual Sensitivity Reported for Some Participants in AGTC’s Achromatopsia Gene Therapy Clinical Trials
Research NewsThe company plans to enroll additional patients as young as four years old
-
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
Foundation NewsNew grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
COVID-19 Resources
Foundation NewsThe Foundation Fighting Blindness is closely monitoring the COVID-19 situation and its impact on the IRD community.
-
ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases
Foundation NewsMy Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
-
Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness launch an open access program for patients with inherited retinal disease in the United States
Foundation NewsThe program will offer patients with inherited retinal disease no-cost genetic testing and genetic counseling in the United States. Look for updated information on how to participate to be posted in mid-October, with program registration starting shortly thereafter.
-
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Foundation NewsBipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
-
Foundation Fighting Blindness Urges Congress to Pass ‘Eye-Bonds’ Legislation
Foundation NewsBill Introduced in U.S. House Would Speed Up Cures for Blindness
-
Foundation Fighting Blindness and CheckedUp® Partner to Educate Retinal-Disease Patients About Research, Resources, and Emerging Therapies During Doctor Visits
Foundation NewsThe Foundation Fighting Blindness (the Foundation) and CheckedUp have formed a collaborative partnership to deliver patient-friendly diagnostic and disease-management information to people with retinal diseases such as age-related macular degeneration, retinitis pigmentosa, and Stargardt disease during their visits to eye doctors.
